eNOS activation by HDL is impaired in genetic CETP deficiency

Monica Gomaraschi, Alice Ossoli, Silvia Pozzi, Peter Nilsson, Angelo B. Cefalù, Maurizio Averna, Jan Albert Kuivenhoven, G. Kees Hovingh, Fabrizio Veglia, Guido Franceschini, Laura Calabresi

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Mutations in the CETP gene resulting in defective CETP activity have been shown to cause remarkable elevations of plasma HDL-C levels, with the accumulation in plasma of large, buoyant HDL particles enriched in apolipoprotein E. Genetic CETP deficiency thus represents a unique tool to evaluate how structural alterations of HDL impact on HDL atheroprotective functions. Aim of the present study was to assess the ability of HDL obtained from CETP-deficient subjects to protect endothelial cells from the development of endothelial dysfunction. HDL isolated from one homozygous and seven heterozygous carriers of CETP null mutations were evaluated for their ability to down-regulate cytokine-induced cell adhesion molecule expression and to promote NO production in cultured endothelial cells. When compared at the same protein concentration, HDL and HDL3 from carriers proved to be as effective as control HDL and HDL3 in down-regulating cytokine-induced VCAM-1, while carrier HDL2 were more effective than control HDL2 in inhibiting VCAM-1 expression. On the other hand, HDL and HDL fractions from carriers of CETP deficiency were significantly less effective than control HDL and HDL fractions in stimulating NO production, due to a reduced eNOS activating capacity, likely because of a reduced S1P content. In conclusion, the present findings support the notion that genetic CETP deficiency, by affecting HDL particle structure, impacts on HDL vasculoprotective functions. Understanding of these effects might be important for predicting the outcomes of pharmacological CETP inhibition.

Original languageEnglish
Article numbere95925
JournalPLoS One
Volume9
Issue number5
DOIs
Publication statusPublished - May 15 2014

Fingerprint

endothelial cells
cytokines
Vascular Cell Adhesion Molecule-1
Chemical activation
Endothelial cells
apolipoprotein E
Endothelial Cells
cell adhesion
cultured cells
Cytokines
Plasmas
Mutation
Cell Adhesion Molecules
Apolipoproteins E
mutation
Cultured Cells
Down-Regulation
Genes
Pharmacology
genes

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Gomaraschi, M., Ossoli, A., Pozzi, S., Nilsson, P., Cefalù, A. B., Averna, M., ... Calabresi, L. (2014). eNOS activation by HDL is impaired in genetic CETP deficiency. PLoS One, 9(5), [e95925]. https://doi.org/10.1371/journal.pone.0095925

eNOS activation by HDL is impaired in genetic CETP deficiency. / Gomaraschi, Monica; Ossoli, Alice; Pozzi, Silvia; Nilsson, Peter; Cefalù, Angelo B.; Averna, Maurizio; Kuivenhoven, Jan Albert; Hovingh, G. Kees; Veglia, Fabrizio; Franceschini, Guido; Calabresi, Laura.

In: PLoS One, Vol. 9, No. 5, e95925, 15.05.2014.

Research output: Contribution to journalArticle

Gomaraschi, M, Ossoli, A, Pozzi, S, Nilsson, P, Cefalù, AB, Averna, M, Kuivenhoven, JA, Hovingh, GK, Veglia, F, Franceschini, G & Calabresi, L 2014, 'eNOS activation by HDL is impaired in genetic CETP deficiency', PLoS One, vol. 9, no. 5, e95925. https://doi.org/10.1371/journal.pone.0095925
Gomaraschi M, Ossoli A, Pozzi S, Nilsson P, Cefalù AB, Averna M et al. eNOS activation by HDL is impaired in genetic CETP deficiency. PLoS One. 2014 May 15;9(5). e95925. https://doi.org/10.1371/journal.pone.0095925
Gomaraschi, Monica ; Ossoli, Alice ; Pozzi, Silvia ; Nilsson, Peter ; Cefalù, Angelo B. ; Averna, Maurizio ; Kuivenhoven, Jan Albert ; Hovingh, G. Kees ; Veglia, Fabrizio ; Franceschini, Guido ; Calabresi, Laura. / eNOS activation by HDL is impaired in genetic CETP deficiency. In: PLoS One. 2014 ; Vol. 9, No. 5.
@article{9c80bd17a76e4c8693ed7355b9703559,
title = "eNOS activation by HDL is impaired in genetic CETP deficiency",
abstract = "Mutations in the CETP gene resulting in defective CETP activity have been shown to cause remarkable elevations of plasma HDL-C levels, with the accumulation in plasma of large, buoyant HDL particles enriched in apolipoprotein E. Genetic CETP deficiency thus represents a unique tool to evaluate how structural alterations of HDL impact on HDL atheroprotective functions. Aim of the present study was to assess the ability of HDL obtained from CETP-deficient subjects to protect endothelial cells from the development of endothelial dysfunction. HDL isolated from one homozygous and seven heterozygous carriers of CETP null mutations were evaluated for their ability to down-regulate cytokine-induced cell adhesion molecule expression and to promote NO production in cultured endothelial cells. When compared at the same protein concentration, HDL and HDL3 from carriers proved to be as effective as control HDL and HDL3 in down-regulating cytokine-induced VCAM-1, while carrier HDL2 were more effective than control HDL2 in inhibiting VCAM-1 expression. On the other hand, HDL and HDL fractions from carriers of CETP deficiency were significantly less effective than control HDL and HDL fractions in stimulating NO production, due to a reduced eNOS activating capacity, likely because of a reduced S1P content. In conclusion, the present findings support the notion that genetic CETP deficiency, by affecting HDL particle structure, impacts on HDL vasculoprotective functions. Understanding of these effects might be important for predicting the outcomes of pharmacological CETP inhibition.",
author = "Monica Gomaraschi and Alice Ossoli and Silvia Pozzi and Peter Nilsson and Cefal{\`u}, {Angelo B.} and Maurizio Averna and Kuivenhoven, {Jan Albert} and Hovingh, {G. Kees} and Fabrizio Veglia and Guido Franceschini and Laura Calabresi",
year = "2014",
month = "5",
day = "15",
doi = "10.1371/journal.pone.0095925",
language = "English",
volume = "9",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "5",

}

TY - JOUR

T1 - eNOS activation by HDL is impaired in genetic CETP deficiency

AU - Gomaraschi, Monica

AU - Ossoli, Alice

AU - Pozzi, Silvia

AU - Nilsson, Peter

AU - Cefalù, Angelo B.

AU - Averna, Maurizio

AU - Kuivenhoven, Jan Albert

AU - Hovingh, G. Kees

AU - Veglia, Fabrizio

AU - Franceschini, Guido

AU - Calabresi, Laura

PY - 2014/5/15

Y1 - 2014/5/15

N2 - Mutations in the CETP gene resulting in defective CETP activity have been shown to cause remarkable elevations of plasma HDL-C levels, with the accumulation in plasma of large, buoyant HDL particles enriched in apolipoprotein E. Genetic CETP deficiency thus represents a unique tool to evaluate how structural alterations of HDL impact on HDL atheroprotective functions. Aim of the present study was to assess the ability of HDL obtained from CETP-deficient subjects to protect endothelial cells from the development of endothelial dysfunction. HDL isolated from one homozygous and seven heterozygous carriers of CETP null mutations were evaluated for their ability to down-regulate cytokine-induced cell adhesion molecule expression and to promote NO production in cultured endothelial cells. When compared at the same protein concentration, HDL and HDL3 from carriers proved to be as effective as control HDL and HDL3 in down-regulating cytokine-induced VCAM-1, while carrier HDL2 were more effective than control HDL2 in inhibiting VCAM-1 expression. On the other hand, HDL and HDL fractions from carriers of CETP deficiency were significantly less effective than control HDL and HDL fractions in stimulating NO production, due to a reduced eNOS activating capacity, likely because of a reduced S1P content. In conclusion, the present findings support the notion that genetic CETP deficiency, by affecting HDL particle structure, impacts on HDL vasculoprotective functions. Understanding of these effects might be important for predicting the outcomes of pharmacological CETP inhibition.

AB - Mutations in the CETP gene resulting in defective CETP activity have been shown to cause remarkable elevations of plasma HDL-C levels, with the accumulation in plasma of large, buoyant HDL particles enriched in apolipoprotein E. Genetic CETP deficiency thus represents a unique tool to evaluate how structural alterations of HDL impact on HDL atheroprotective functions. Aim of the present study was to assess the ability of HDL obtained from CETP-deficient subjects to protect endothelial cells from the development of endothelial dysfunction. HDL isolated from one homozygous and seven heterozygous carriers of CETP null mutations were evaluated for their ability to down-regulate cytokine-induced cell adhesion molecule expression and to promote NO production in cultured endothelial cells. When compared at the same protein concentration, HDL and HDL3 from carriers proved to be as effective as control HDL and HDL3 in down-regulating cytokine-induced VCAM-1, while carrier HDL2 were more effective than control HDL2 in inhibiting VCAM-1 expression. On the other hand, HDL and HDL fractions from carriers of CETP deficiency were significantly less effective than control HDL and HDL fractions in stimulating NO production, due to a reduced eNOS activating capacity, likely because of a reduced S1P content. In conclusion, the present findings support the notion that genetic CETP deficiency, by affecting HDL particle structure, impacts on HDL vasculoprotective functions. Understanding of these effects might be important for predicting the outcomes of pharmacological CETP inhibition.

UR - http://www.scopus.com/inward/record.url?scp=84901324767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901324767&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0095925

DO - 10.1371/journal.pone.0095925

M3 - Article

C2 - 24830642

AN - SCOPUS:84901324767

VL - 9

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 5

M1 - e95925

ER -